AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Inotuzumab ozogamicin is safe and effective in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia, ...

AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant ...

Summary: The SteamOS version of the Lenovo Legion Go S is now available for pre-order, and it has a higher price than ...

Walt Disney World is offering a rare sale on tickets for kids this summer. The theme park has announced a 50% discount on ...

Alan Tan, MD, discusses the 8-year follow-up data from the CheckMate 214 trial of patients with advanced renal cell carcinoma.

在数字化飞速发展的今天，无论是硬核电竞玩家追求极致游戏体验，还是企业搭建高效网络环境，一张性能卓越的网卡都至关重要。IO-PCE1131-GLAN ...

SaaS Scale Announces New GTM Playbook and Revenue Operating System for High-Growth Startups.London, UK, March 27, 2025 -- In a market where B2B ...

Shiba Inu Treat (TREAT) gains 4.65% as spot volume explodes 219%. Derivatives interest grows for key Shib OS utility token amid bullish signals.